These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29452147)

  • 41. Early requirement of Rac1 in a mouse model of pancreatic cancer.
    Heid I; Lubeseder-Martellato C; Sipos B; Mazur PK; Lesina M; Schmid RM; Siveke JT
    Gastroenterology; 2011 Aug; 141(2):719-30, 730.e1-7. PubMed ID: 21684285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer.
    Ma L; Saiyin H
    PLoS One; 2017; 12(5):e0176844. PubMed ID: 28475592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN.
    Siveke JT; Einwächter H; Sipos B; Lubeseder-Martellato C; Klöppel G; Schmid RM
    Cancer Cell; 2007 Sep; 12(3):266-79. PubMed ID: 17785207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A case of mistaken identity? Nonductal origins of pancreatic "ductal" cancers.
    Murtaugh LC; Leach SD
    Cancer Cell; 2007 Mar; 11(3):211-3. PubMed ID: 17349578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.
    Wang LJ; He CC; Sui X; Cai MJ; Zhou CY; Ma JL; Wu L; Wang H; Han SX; Zhu Q
    Oncotarget; 2015 Mar; 6(8):5932-46. PubMed ID: 25803229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis.
    Flandez M; Cendrowski J; Cañamero M; Salas A; del Pozo N; Schoonjans K; Real FX
    Gut; 2014 Apr; 63(4):647-55. PubMed ID: 23598351
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States.
    Altekruse SF; Petrick JL; Rolin AI; Cuccinelli JE; Zou Z; Tatalovich Z; McGlynn KA
    PLoS One; 2015; 10(3):e0120574. PubMed ID: 25837669
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
    Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
    Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
    Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
    Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mouse Model for Cholangiocarcinoma from Peribiliary Glands.
    Nakagawa H; Suzuki N; Koike K
    Methods Mol Biol; 2019; 1905():237-245. PubMed ID: 30536105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutational landscape of intrahepatic cholangiocarcinoma.
    Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
    Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The uterine epithelial loss of Pten is inefficient to induce endometrial cancer with intact stromal Pten.
    Liang X; Daikoku T; Terakawa J; Ogawa Y; Joshi AR; Ellenson LH; Sun X; Dey SK
    PLoS Genet; 2018 Aug; 14(8):e1007630. PubMed ID: 30142194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancing PTEN suppressor gene expression in pancreatic carcinoma.
    Petrogiannopoulos L; Niotis A; Niotis T; Tsiambas E
    J BUON; 2020; 25(1):582. PubMed ID: 32277687
    [No Abstract]   [Full Text] [Related]  

  • 55. Kras activation in endometrial organoids drives cellular transformation and epithelial-mesenchymal transition.
    Maru Y; Tanaka N; Tatsumi Y; Nakamura Y; Itami M; Hippo Y
    Oncogenesis; 2021 Jun; 10(6):46. PubMed ID: 34172714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kras in Organoids.
    Cheng D; Tuveson D
    Cold Spring Harb Perspect Med; 2018 Oct; 8(10):. PubMed ID: 29311127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhancing PTEN suppressor gene expression in pancreatic carcinoma.
    Petrogiannopoulos L; Niotis A; Niotis T; Tsiambas E
    J BUON; 2020; 25(3):1664. PubMed ID: 32862621
    [No Abstract]   [Full Text] [Related]  

  • 58. Kras-driven heterotopic tumor development from hepatobiliary organoids.
    Ochiai M; Yoshihara Y; Maru Y; Matsuura T; Izumiya M; Imai T; Hippo Y
    Carcinogenesis; 2019 Sep; 40(9):1142-1152. PubMed ID: 30753336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-target genetic manipulation induces rhabdomyosarcoma in
    Lai H; Guo Y; He W; Sun T; Ouyang L; Tian L; Li Y; Li X; You Z; Yang G
    Transl Cancer Res; 2020 Dec; 9(12):7458-7468. PubMed ID: 35117346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?
    Ferreira RG; Narvaez LEM; Espíndola KMM; Rosario ACRS; Lima WGN; Monteiro MC
    Front Oncol; 2021; 11():594917. PubMed ID: 34354940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.